The role of curcumin in liver diseases

Buonomo, Antonio Riccardo; Scotto, Riccardo; Nappa, Salvatore; Arcopinto, Michele; Salzano, Andrea; Marra, Alberto M.; D’Assante, Roberta; Zappulo, Emanuela; Borgia, Guglielmo; Gentile, Ivan

doi:10.5114/aoms.2018.73596

Cited by 20 publications

(12 citation statements)

References 128 publications

(129 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of liver diseases has undergone an increase due to lifestyle. They are commonly occur in patients who suffer from obesity and alcohol abuse ( Buonomo et al, 2019 ). The liver fibrosis is a chronic liver disease in which extracellular proteins such as collagen accumulate.…”

Section: Curcumin and Transforming Growth Factor-beta In Different DImentioning

confidence: 99%

Toward Regulatory Effects of Curcumin on Transforming Growth Factor-Beta Across Different Diseases: A Review

et al. 2020

View full text Add to dashboard Cite

Immune response, proliferation, migration and angiogenesis are juts a few of cellular events that are regulated by transforming growth factor-β (TGF-β) in cells. A number of studies have documented that TGF-β undergoes abnormal expression in different diseases, e.g., diabetes, cancer, fibrosis, asthma, arthritis, among others. This has led to great fascination into this signaling pathway and developing agents with modulatory impact on TGF-β. Curcumin, a natural-based compound, is obtained from rhizome and roots of turmeric plant. It has a number of pharmacological activities including antioxidant, anti-inflammatory, anti-tumor, anti-diabetes and so on. Noteworthy, it has been demonstrated that curcumin affects different molecular signaling pathways such as Wnt/β-catenin, Nrf2, AMPK, mitogen-activated protein kinase and so on. In the present review, we evaluate the potential of curcumin in regulation of TGF-β signaling pathway to corelate it with therapeutic impacts of curcumin. By modulation of TGF-β (both upregulation and down-regulation), curcumin ameliorates fibrosis, neurological disorders, liver disease, diabetes and asthma. Besides, curcumin targets TGF-β signaling pathway which is capable of suppressing proliferation of tumor cells and invading cancer cells.

show abstract

Section: Curcumin and Transforming Growth Factor-beta In Different DImentioning

confidence: 99%

Toward Regulatory Effects of Curcumin on Transforming Growth Factor-Beta Across Different Diseases: A Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Meanwhile, curcumin improved lipid accumulation in nonalcoholic fatty liver disease via increasing PPAR α mRNA and protein levels in the liver and inhibition of DNA methylation at the PPAR α gene [ 26 ]. Thus, curcumin may prevent nonalcoholic steatohepatitis (NASH)/cirrhosis and nonalcoholic fatty liver disease through direct/indirect induction of PPAR γ expression [ 27 ].…”

Section: Phytochemicals With Ppar Modulation Activitiesmentioning

confidence: 99%

Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments

et al. 2022

View full text Add to dashboard Cite

Peroxisome proliferator-activated receptors (PPARs) are members of the ligand-dependent nuclear receptor family. PPARs have attracted wide attention as pharmacologic mediators to manage multiple diseases and their underlying signaling targets. They mediate a broad range of specific biological activities and multiple organ toxicity, including cellular differentiation, metabolic syndrome, cancer, atherosclerosis, neurodegeneration, cardiovascular diseases, and inflammation related to their up/downstream signaling pathways. Consequently, several types of selective PPAR ligands, such as fibrates and thiazolidinediones (TZDs), have been approved as their pharmacological agonists. Despite these advances, the use of PPAR agonists is known to cause adverse effects in various systems. Conversely, some naturally occurring PPAR agonists, including polyunsaturated fatty acids and natural endogenous PPAR agonists curcumin and resveratrol, have been introduced as safe agonists as a result of their clinical evidence or preclinical experiments. This review focuses on research on plant-derived active ingredients (natural phytochemicals) as potential safe and promising PPAR agonists. Moreover, it provides a comprehensive review and critique of the role of phytochemicals in PPARs-related diseases and provides an understanding of phytochemical-mediated PPAR-dependent and -independent cascades. The findings of this research will help to define the functions of phytochemicals as potent PPAR pharmacological agonists in underlying disease mechanisms and their related complications.

show abstract

“…These results can be explained by the fact that curcumin has a cellular membrane-stabilizing property so it reduces cellular destruction [42]. Even more, curcumin seems to be able to reduce liver damage by inhibition of hepatic stellate cell (HSC) activation, as activation of HSC promotes liver fibrosis regardless of etiology [43].…”

Section: Serum Levels Of Liver Function Parameters and Liver Histopat...mentioning

confidence: 99%

Multi-Organ Protective Effects of Curcumin Nanoparticles on Drug-Induced Acute Myocardial Infarction in Rats with Type 1 Diabetes Mellitus

Boarescu

Bulboacă

et al. 2021

Applied Sciences

View full text Add to dashboard Cite

The objectives of this study were to investigate the cardio-protective, hepatoprotective and nephroprotective effects of curcumin nanoparticle (NC) pretreatment compared to conventional curcumin (CC) on acute myocardial infarction (AMI) in rats with type 1 diabetes mellitus (T1DM). Fifty-six Wister Bratislava rats were divided into eight groups. The first four groups—C (control group), AMI (group with AMI), T1DM (group with T1DM), and T1DM-AMI (group with T1DM and AMI)—received only saline (S) during the whole experiment. Two groups—S-T1DM-CC-AMI and S-T1DM-NC-AMI—were pretreated with S before T1DM induction. The S-T1DM-CC-AMI group received CC (200 mg/Kg bw (bw—body weight)) after T1DM induction, while the S-T1DM-NC-AMI group received NC (200 mg/Kg bw) after T1DM induction. the CC-T1DM-CC-AMI group received CC (200 mg/Kg bw) during the whole experiment. Similarly, the NC-T1DM-NC-AMI group received NC (200 mg/Kg bw) over the entire experiment. T1DM was induced on day 7 using a single dose of streptozotocin (STZ). AMI was induced with isoproterenol (ISO) on day 22. Both curcumin formulations, CC and NC, prevented the following electrocardiographic changes: prolongation of the QRS complex, enlargement of QT and QTc intervals, and ST-segment elevation. Glucose levels and lipid profile parameters were reduced up to 1.9 times, while C-peptide serum levels were increased up to 1.6 times in groups that received CC or NC. Liver function parameters (aspartate transaminase, alanine transaminase) and kidney function parameters (creatinine, urea) were reduced 4.8 times, and histological changes of liver and kidney tissue were improved by CC or NC administration. Pretreatment with NC proved significantly higher cardioprotective, hepatoprotective and nephroprotective effects in the case of AMI in T1DM.

show abstract

The role of curcumin in liver diseases

Cited by 20 publications

References 128 publications

Toward Regulatory Effects of Curcumin on Transforming Growth Factor-Beta Across Different Diseases: A Review

Toward Regulatory Effects of Curcumin on Transforming Growth Factor-Beta Across Different Diseases: A Review

Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments

Multi-Organ Protective Effects of Curcumin Nanoparticles on Drug-Induced Acute Myocardial Infarction in Rats with Type 1 Diabetes Mellitus

Contact Info

Product

Resources

About